Cancer breakthrough may open the door to new era of immunotherapy treatment

A ground-breaking “off the shelf” immunotherapy treatment for cancer has moved a significant step closer following research by a leading US university.

Researchers from UCLA have reported a critical step forward in the development of an “off-the-shelf” cancer immunotherapy using rare but powerful immune cells that could potentially be produced in large quantities, stored for extended periods and safely used to treat a wide range of patients with various cancers.

It is a huge step forward for the potential treatment of a wide range of cancers. Currently immunotherapies, which harness the body’s natural defences to combat disease, have revolutionised the treatment of aggressive and deadly cancers. But often, these therapies, especially those based on immune cells, must be tailored to the individual patient, costing valuable time and pushing their price into the hundreds of thousands of dollars.

“In order to reach the most patients, we want cell therapies that can be mass-produced, frozen and shipped to hospitals around the world,” said Lili Yang, a member of the Eli and Edythe Broad Centre of Regenerative Medicine and Stem Cell Research at UCLA and the study’s senior author. “That way, doses of these therapies can be ready and waiting for patients as soon as they are needed.”

For the study, Yang and her colleagues focused on invariant natural killer T cells, or iNKT cells, which are unique not only for their power and efficacy but also because they don’t carry the risk of graft-versus-host disease, which occurs when transplanted cells attack a recipient’s body and which is the reason most cell-based immunotherapies must be created on a patient-specific basis, Yang said.

The researchers developed a new method for producing large numbers of these iNKT cells using blood-forming stem cells, which can self-replicate and produce all kinds of blood and immune cells. The team used stem cells obtained from four donor cord-blood samples and eight donor peripheral blood samples.

“Our findings suggest that one cord blood donation could produce up to 5,000 doses of the therapy and one peripheral blood donation could produce up to 300,000 doses,” said Yang, who is also an associate professor of microbiology, immunology and molecular genetics and a member of the UCLA Jonsson Comprehensive Cancer Centre. ­­“At this yield, the cost of producing immune cell products could be dramatically reduced.”

The researchers first used genetic engineering to program the blood-forming stem cells to make them more likely to develop into iNKT cells. Next, these genetically engineered stem cells were placed into artificial thymic organoids, which mimic the environment of the thymus, a specialized organ in which T cells naturally mature in the body. After eight weeks in the organoids, each stem cell produced, on average, 100,000 iNKT cells.

Yang and her colleagues then tested the resulting cells, called hematopoietic stem cell-engineered iNKT cells, or HSC–iNKT cells, by comparing their cancer-fighting abilities with those of immune cells called natural killer cells, or NK cells. In a lab dish, the HSC–iNKT cells were significantly better at killing multiple types of human tumour cells — including leukaemia, melanoma, lung cancer, prostate cancer and multiple myeloma cells — than the NK cells, the researchers found.

Even more importantly, the HSC–iNKT cells sustained their tumour-killing efficacy after being frozen and thawed, an essential requirement for widespread distribution of an off-the-shelf cell therapy.

The researchers said they are now working to improve their manufacturing methods by moving to a feeder-free system that eliminates the need for supportive cells — such as those used in the thymic organoids — to assist blood stem cells in producing iNKT cells. Yang says she hopes this advance will better enable mass-production of the therapy and, ultimately, its clinical and commercial development.

Follow us on twitter: @risksEmerging

MobaXterm Professional Edition v21.5.0.4826 Full Activated – Discount 100% OFF https://www.dr-farfar.com/mobaxterm-professional-edition/ #infosec #bugcrowd #bugbountytips #bugbountytip #CyberSecurity #100DaysOfCode #Malware #CodeNewbie #BugHunter #Javascript via @3XS0

Angry employee stole his company’s data, blackmailed the bosses https://cyberiqs.com/angry-employee-stole-his-companys-data-blackmailed-the-bosses-and-dropped-their-stock-by-20-best-example-of-insider-threat/ #infosec #infosecurity #cybersecurity #threatintel #threatintelligence #hacking #cybernews #cyberattack #threathunting #cloudsecurity #cloudcomputing #malware #ransomware #devops #dfir #cyber

An automated solution for background screening of candidates?
We're here. 😉

#MachineLearning #DataScience #5G #100DaysOfCode #Python #Cybersecurity #BigData #AI #IoT #DeepLearning #ArtificialIntelligence #NLP #robots #Industry40 #tech #DEVCommunity
#javascript #TechnoSupport https://twitter.com/HungLee/status/1462711663904362500

Hung Lee@HungLee

'Negative Content' Breakdown

Out of 9708 sampled job seekers who underwent social media background screening (with consent), instances of negative content was distributed as follows 👇

Sexism in the lead, followed closely by Homophobia

USA best quality service http://Usatopservices.com
#buy_google_reviews
#buy_google_5_star_reviews

#pokemon #blacktechtwitter #Cybersecurity #usatopservices #infosec #100DaysOfCode #node #nodejs #coding #js #angularjs #reactjs #tech #javascript #html #womenwhocode #301DaysOfCode

Uganda launches road-building in Congo to boost trade http://reut.rs/3pwWOO2

Former GOP Sen. David Perdue plans to announce Monday that he's mounting a primary challenge against Georgia Gov. Brian Kemp, multiple reports say https://cnn.it/3InqRAj

17 Malware Frameworks Target Air-Gapped Systems for Espionage |
#cyberdefense #cybersecurity #infosec #informationsecurity #datasecurity #insiderthreat #vulnerabilitymanagement #devsecops #endpointsecurity
https://www.securityweek.com/17-malware-frameworks-target-air-gapped-systems-espionage

Didi Global shares plunge more than 20% on plan to delist from NYSE

https://www.business-standard.com/article/international/didi-global-shares-plunge-more-than-20-on-plan-to-delist-from-nyse-121120400065_1.html

#cybersecurity #infosec

Load More...
SHARE: